State Street Health Care Select Sector SPDR ETF (XLV)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
State Street Health Care Select Sector SPDR ETF (XLV) with AI Score 49/100 (Weak). The State Street Health Care Select Sector SPDR ETF (XLV) mirrors the Health Care Select Sector Index, offering targeted exposure to the U. S. healthcare industry. Market cap: 0, Sector: Financial services.
Last analyzed: Mar 17, 2026State Street Health Care Select Sector SPDR ETF (XLV) Financial Services Profile
State Street Health Care Select Sector SPDR ETF (XLV) provides investors with focused exposure to the health care sector of the S&P 500, tracking companies in pharmaceuticals, biotechnology, and healthcare services. With a market cap of $39.58 billion, it offers a strategic tool for targeted investment in the U.S. healthcare market.
Investment Thesis
The State Street Health Care Select Sector SPDR ETF (XLV) presents a targeted investment vehicle for those seeking exposure to the U.S. healthcare sector. With a beta of 0.65, it demonstrates lower volatility compared to the broader market. The fund's focus on pharmaceuticals, biotechnology, and healthcare services positions it to benefit from long-term trends such as an aging population and advancements in medical technology. However, regulatory changes and potential drug pricing pressures represent ongoing risks. The ETF's performance is directly tied to the performance of the Health Care Select Sector Index, making it crucial to monitor the overall health and outlook of the U.S. healthcare industry.
Based on FMP financials and quantitative analysis
Key Highlights
- Market Cap of $39.58 billion, reflecting its significant presence in the asset management space.
- Beta of 0.65, indicating lower volatility compared to the broader market, potentially offering a more stable investment.
- Exposure to the Health Care Select Sector Index, providing targeted access to the U.S. healthcare sector.
- Holdings include companies in pharmaceuticals, biotechnology, and healthcare services, diversifying exposure within the healthcare industry.
- Managed by State Street Global Advisors, a reputable asset management firm with extensive experience in ETFs.
Competitors & Peers
Strengths
- Targeted exposure to the U.S. healthcare sector.
- Diversification across multiple healthcare industries.
- Low expense ratio compared to actively managed funds.
- Managed by a reputable asset management firm.
Weaknesses
- Concentration in a single sector, increasing risk.
- Vulnerability to regulatory changes in the healthcare industry.
- Dependence on the performance of the Health Care Select Sector Index.
- No dividend yield.
Catalysts
- Upcoming: Potential for new drug approvals and therapies to boost performance of pharmaceutical and biotechnology companies within the ETF.
- Ongoing: Aging population driving increased demand for healthcare services and products.
- Ongoing: Technological advancements in medical devices and healthcare technology improving patient outcomes and driving industry growth.
Risks
- Potential: Regulatory changes and drug pricing pressures impacting profitability of pharmaceutical companies.
- Potential: Economic downturns reducing healthcare spending and impacting demand for healthcare services.
- Ongoing: Competition from other healthcare-focused ETFs and investment vehicles.
- Ongoing: Dependence on the performance of the Health Care Select Sector Index, which may be affected by broader market trends.
Growth Opportunities
- Aging Population: The global population is aging, leading to increased demand for healthcare services and products. This demographic shift is expected to drive growth in the healthcare sector, benefiting companies held within the XLV ETF. As the elderly population grows, the demand for pharmaceuticals, medical devices, and healthcare services will likely increase, creating a favorable environment for the ETF's holdings. The United Nations projects that the number of people aged 60 years or over will double by 2050, creating a significant long-term growth opportunity.
- Technological Advancements: Rapid advancements in medical technology, such as gene therapy, robotic surgery, and artificial intelligence, are transforming the healthcare industry. Companies developing and implementing these technologies are poised for growth, potentially boosting the performance of the XLV ETF. The global market for medical technology is projected to reach $600 billion by 2025, driven by innovation and increasing healthcare spending.
- Emerging Markets: As emerging markets experience economic growth, healthcare spending is expected to increase, creating new opportunities for healthcare companies. The XLV ETF, with its exposure to leading healthcare companies, may benefit from this trend. The growing middle class in emerging markets is driving demand for better healthcare services and access to advanced medical treatments, leading to increased investment in the healthcare sector.
- Drug Development: The pharmaceutical and biotechnology industries are constantly developing new drugs and therapies to treat a wide range of diseases. Successful drug development can lead to significant revenue growth for companies, positively impacting the XLV ETF. The global pharmaceutical market is projected to reach $1.5 trillion by 2023, driven by new drug approvals and increasing healthcare spending.
- Healthcare Reform: Changes in healthcare policy and regulations can create both opportunities and challenges for the healthcare industry. However, reforms aimed at expanding access to healthcare and improving quality of care could benefit companies within the XLV ETF. For example, policies that encourage the use of generic drugs or promote preventive care could lead to increased demand for certain healthcare products and services.
Opportunities
- Growth in the healthcare sector driven by an aging population.
- Advancements in medical technology creating new investment opportunities.
- Increased demand for healthcare services in emerging markets.
- Potential for new drug approvals and therapies to boost performance.
Threats
- Regulatory changes and drug pricing pressures.
- Economic downturns impacting healthcare spending.
- Competition from other healthcare-focused ETFs.
- Unexpected events, such as pandemics, disrupting the healthcare industry.
Competitive Advantages
- Established Brand: State Street is a well-known and respected asset manager with a long history of providing investment solutions.
- Index Tracking: The ETF's performance is tied to a well-established index, providing transparency and predictability.
- Scale: The ETF's large asset base allows it to operate efficiently and offer competitive expense ratios.
About XLV
The State Street Health Care Select Sector SPDR ETF (XLV) was created to replicate, before fees and expenses, the price and yield performance of the Health Care Select Sector Index. This index is designed to represent the healthcare sector within the broader S&P 500, offering investors a way to concentrate their investments in this specific area of the market. XLV provides exposure to a range of healthcare-related industries, including pharmaceuticals, healthcare equipment and supplies, healthcare providers and services, biotechnology, life sciences tools and services, and healthcare technology. By focusing on these specific segments, XLV allows investors to take strategic or tactical positions in the healthcare sector, offering a more targeted approach compared to broader market investments. The ETF's holdings are weighted by market capitalization, meaning that larger companies within the index have a greater impact on its overall performance. XLV is managed by State Street Global Advisors, a well-established asset management firm with a long history of providing investment solutions to a wide range of clients. The ETF is based in Boston, USA, and is designed to provide precise exposure to the U.S. healthcare market.
What They Do
- Tracks the performance of the Health Care Select Sector Index.
- Provides exposure to companies in the pharmaceuticals industry.
- Offers access to companies in the biotechnology industry.
- Includes companies in the healthcare equipment and supplies industry.
- Invests in companies in the healthcare providers and services industry.
- Covers companies in the life sciences tools and services industry.
- Targets companies in the healthcare technology industry.
Business Model
- The ETF generates revenue through management fees charged to investors.
- The fund's performance is directly linked to the performance of the underlying Health Care Select Sector Index.
- State Street Global Advisors manages the ETF and is responsible for its investment strategy and operations.
Industry Context
The asset management industry is characterized by a diverse range of investment products, including ETFs, mutual funds, and hedge funds. The State Street Health Care Select Sector SPDR ETF (XLV) operates within this industry by offering a specialized investment product focused on the healthcare sector. The ETF competes with other healthcare-focused funds and broader market ETFs. The healthcare sector itself is influenced by factors such as demographic trends, technological advancements, and regulatory changes. As the population ages and demand for healthcare services increases, ETFs like XLV may benefit from increased investor interest.
Key Customers
- Institutional investors seeking targeted exposure to the U.S. healthcare sector.
- Retail investors looking for a convenient way to invest in a diversified portfolio of healthcare stocks.
- Financial advisors using ETFs as part of their clients' investment portfolios.
Financials
Chart & Info
State Street Health Care Select Sector SPDR ETF (XLV) stock price: Price data unavailable
Latest News
-
Leading And Lagging Sectors For March 31, 2026
benzinga · Mar 31, 2026
-
Leading And Lagging Sectors For March 30, 2026
benzinga · Mar 30, 2026
-
Sector Update: Health Care Stocks Decline Premarket Friday
MT Newswires · Mar 27, 2026
-
Leading And Lagging Sectors For March 27, 2026
benzinga · Mar 27, 2026
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for XLV.
Price Targets
Wall Street price target analysis for XLV.
MoonshotScore
What does this score mean?
The MoonshotScore rates XLV's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Latest State Street Health Care Select Sector SPDR ETF Analysis
XLV Financial Services Stock FAQ
What does State Street Health Care Select Sector SPDR ETF do?
The State Street Health Care Select Sector SPDR ETF (XLV) is designed to track the performance of the Health Care Select Sector Index, providing investors with targeted exposure to the U.S. healthcare sector. The ETF invests in a diversified portfolio of companies within the pharmaceuticals, biotechnology, healthcare equipment and supplies, healthcare providers and services, life sciences tools and services, and healthcare technology industries. By investing in XLV, investors can gain access to a broad range of healthcare companies without having to individually select stocks, offering a convenient and cost-effective way to participate in the growth of the healthcare sector.
What do analysts say about XLV stock?
Analyst consensus for the State Street Health Care Select Sector SPDR ETF (XLV) generally reflects the outlook for the broader healthcare sector. Key valuation metrics, such as the price-to-earnings ratio and price-to-book ratio, are often compared to those of other healthcare ETFs and the overall market. Growth considerations typically focus on factors such as demographic trends, technological advancements, and regulatory changes impacting the healthcare industry. While analysts may provide price targets and ratings, it's important to conduct independent research and consider your own investment objectives before making any decisions. AI analysis is currently pending for XLV.
What are the main risks for XLV?
The State Street Health Care Select Sector SPDR ETF (XLV) faces several risks, including regulatory changes, drug pricing pressures, and economic downturns. Regulatory changes, such as those related to healthcare reform or drug approvals, can significantly impact the profitability of healthcare companies. Drug pricing pressures, driven by government policies or market competition, can also reduce revenue for pharmaceutical companies. Economic downturns can lead to reduced healthcare spending, impacting demand for healthcare services and products. Additionally, competition from other healthcare-focused ETFs and investment vehicles poses a risk to XLV's market share.
What are the key factors to evaluate for XLV?
State Street Health Care Select Sector SPDR ETF (XLV) currently holds an AI score of 49/100, indicating low score. Key strength: Targeted exposure to the U.S. healthcare sector.. Primary risk to monitor: Potential: Regulatory changes and drug pricing pressures impacting profitability of pharmaceutical companies.. This is not financial advice.
How frequently does XLV data refresh on this page?
XLV prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven XLV's recent stock price performance?
Recent price movement in State Street Health Care Select Sector SPDR ETF (XLV) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Targeted exposure to the U.S. healthcare sector.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider XLV overvalued or undervalued right now?
Determining whether State Street Health Care Select Sector SPDR ETF (XLV) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying XLV?
Before investing in State Street Health Care Select Sector SPDR ETF (XLV), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- AI analysis pending for XLV, which may provide further insights.
- The ETF's performance is dependent on the performance of the Health Care Select Sector Index.
- Regulatory changes in the healthcare industry can significantly impact the ETF's performance.